Trials / Conditions / Ebola

Ebola

12 registered clinical trials studyying Ebola.

Status	Trial	Sponsor	Phase
Completed	Long-Term Neurologic and Neurocognitive Sequelae Following Pediatric Ebola Virus in Liberia NCT06811129	National Institute of Neurological Disorders and Stroke (NINDS)	—
Completed	Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Sa NCT05284097	London School of Hygiene and Tropical Medicine	Phase 2
Unknown	A Study in Tanzania of a New Vaccine Against Two Types of Ebola NCT05301504	University of Oxford	Phase 1
Completed	A Study of a New Vaccine Against Two Types of Ebola NCT05079750	University of Oxford	Phase 1
Completed	Ad26.ZEBOV Booster in HIV+ Adults Previously Vaccinated With Ad26.ZEBOV/MVA-BN-Filo (EBOVAC HIV+ Booster Study NCT05064956	London School of Hygiene and Tropical Medicine	Phase 2
Completed	Drug-drug Interactions Between Remdesivir and Commonly Used Antiretroviral Therapy NCT04385719	Makerere University	Phase 2
Completed	A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants NCT04228783	Janssen Vaccines & Prevention B.V.	Phase 3
Completed	African-Canadian Study of HIV-Infected Adults and a Vaccine for Ebola - ACHIV-Ebola NCT03031912	Canadian Immunization Research Network	Phase 2
Completed	GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survi NCT02818582	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2
Completed	Study to Evaluate the Immunogenicity and Safety of an Ebola Virus (EBOV) Glycoprotein (GP) Vaccine in Healthy NCT02370589	Novavax	Phase 1
Completed	A Study to Assess New Ebola Vaccines, cAd3-EBO Z and MVA-BN® Filo NCT02240875	University of Oxford	Phase 1
Completed	Poly-ICLC to Prevent Respiratory Viral Infections A Safety Study NCT00646152	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1